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respectively.Summary Intrapulmonary percussive ventilation (IPV) is a ventilatory technique
that delivers bursts of high-flow respiratory gas into the lung at high rates, intended
for treating acute respiratory failure and for mobilization of secretions. We
performed a study, aimed at assessing the physiological response to IPV, on patients’
breathing pattern, inspiratory effort, lung mechanics and tolerance to ventilation.
Ten COPD patients underwent randomized trials of IPV through a face mask
at different pressure/frequency combinations (1.2 bar/250 cycles/min; 1.8/250;
1.2/350; 1.8/350), separated by return to baseline (SB), using the IMP2 ventilator.
In 5 patients we have also compared the physiological changes of IPV with those
obtained during pressure support ventilation (PSV).
Minute ventilation did not vary among the trials, but tidal volumes (VT) were
significantly greater during 1.2/250, 1.2/350 and 1.8/350 compared to SB. The
pressure time product of the diaphragm per minute (PTPdi/min) estimate of the
diaphragm oxygen expenditure was also significantly reduced during 1.2/250 and
1.8/250 (209 cmH2O s/min for SB vs. 143 and 125 for 1.2/250 and 1.8/250,
respectively Po0.05), as well as dynamic intrinsic end-expiratory pressure
(PEEPi,dyn). Similar reduction in PTPdi/min were obtained also during PSV. Tolerance
to ventilation and oxygen saturation were satisfactory and did not change during the
different trials. In 5 normal subjects a prolonged apnea trial lasting42min was also
performed, without any significant decrease in SaO2 or subjective discomfort. In
conclusion, IPV was able to guarantee an adequate ventilation, while inducing a
significant unloading of the diaphragm during the ‘‘low-frequency’’ trials.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Table 1 Patients’ characteristics at enrolment.
Variable
Age (years) 65.276.7
Sex (M/F) 8/2
pH 7.3770.02
PaCO2 (mmHg) 52.378.1
PaO2 (mmHg) 53.177.0
FVC (% predicted) 89711
FEV1 (% predicted) 3179
FEV1/FVC 3578
Physiological effects of percussive ventilation 1527Introduction
Intrapulmonary percussive ventilation (IPV) is a
ventilatory technique that delivers small bursts of
high flow respiratory gas into the lung at high rates,1
intended for mobilization of secretions that has been
employed in several pathologies, characterized by
excessive secretion, both in adults and children.2–5 In
a very recent randomized-controlled study 6 con-
ducted in ICU and performed in COPD patients with
initial respiratory acidosis, IPV has been shown to
prevent the deterioration of acute exacerbation,
avoiding therefore the use of invasive mechanical
ventilation. Potential mechanisms of actions include
enhanced alveolar recruitment, improved mucus
clearance, and/or a direct high-frequency oscillatory
ventilation like effect.1 Surprisingly, so far no study
has been performed to evaluate the physiological
changes induced by IPV. In order to better under-
stand the effects of this modality of ventilation, we
describe the changes of IPV on breathing pattern,
diaphragmatic function, respiratory mechanics and
patient’s tolerance in stable COPDs with chronic
respiratory failure, and we compared, in a subset
patients, those effects with the ones obtained during
non-invasive pressure support ventilation (PSV). We
also verify the potentiality of IPV in providing
effective ventilation during a prolonged apnea trial
in a group of normal subjects.
Materials and methods
Patients
Ten severe COPD patients, with minimal mucus
hypersecretion (o10ml/d) naı¨ve to ventilation,
and affected by chronic hypercapnic respiratory
failure were studied during a phase of clinical
stability during sessions of IPV. Clinical stability was
defined as the absence of exacerbations of their
respiratory disease in the preceding 3 months. The
patients were admitted to the hospital for a
scheduled short control of their clinical conditions.
The quantity of mucus secretion was assessed
asking the patients to collect their sputum in a
box for the 48 h preceding the experimental trial.
Collection and quantification of sputum weight was
performed every 12 h. Patients’ characteristics are
illustrated in Table 1. All the patients were on long-
term oxygen therapy.
Intervention
IPV is a ventilatory versatile form of high-frequency
ventilation (HFV) that delivers bursts of high-flowrespiratory gas in the lung at high respiratory rates.
HFV techniques have three essential common
elements: a high-pressure flow generator, a valve
for flow interruption, and a breathing circuit for
connection to the patients. Many variants of this
definition were further developed as flow interrup-
tion ventilation (HFFI), high-frequency oscillation
(HFO) and high-frequency positive pressure ventila-
tion (HFPPV) based on the specific techniques that
discriminate them. Similar to HFV, IPV delivers
subphysiologic tidal volumes (VT) at rapid rates.
Unique to the IPV is the presence of a sliding
venturi system (phasitron), powered by compressed
gas that can be changed from 0.8 up to 3.5 bar and
that generates the oscillations in the range of
80–650 cycles/min.7 During this ventilation a
continuous positive pressure is maintained, while
a high-velocity percussive inflow opens airways and
enhances intra-bronchial secretion mobilization.
During IPV the high pressures generated by the
ventilator are mostly dissipated in the mask and in
the upper airways. IPV was delivered with a specific
ventilator (IMP2, Breas Medical Mo¨lnlycke, Sweden)
through a full face mask. The inspiration-to-
expiration time (I=E ratio) was adjusted to 1/2.5
and the proximal expiratory pressure was set to
3 cmH2O. The I=E ratio of the administered oscilla-
tory flow pattern generated by the device (that is
independent of the patient’s breathing pattern)
was set at 1/2.5 because this was the setting used
in the only clinical study performed in COPD
patients with respiratory failure.6 Indeed, since
the setting of the I=E ratio influences the mean
airway pressure, it was recommended by the
distributors of the device, the use of a 1/2.5 ratio
in COPD patients, to avoid pressure higher than
30 cmH2O.Protocol
First trial
As illustrated in Fig. 1, upper part, 10 COPD
patients were randomly assigned to 4 sessions of
ARTICLE IN PRESS
S. Nava et al.1528IPV, at different pressure/frequency combinations
lasting 10min each and separated by return to
spontaneous breathing (SB) for 15min. This time
was always long enough to allow a complete return
to baseline conditions of the main physiological
variables (see ‘‘Results’’), and therefore to avoid
any carry-over effect. The following sessions were
performed by the trained respiratory therapist:
frequency of percussion of 250/min using a driving
pressure of the apparatus of 1.2 bar (1.2/250) and
1.8 bar (1.8/250), respectively, and frequency of
percussion of 350/min using a driving pressure of
1.2 bar (1.2/350) and 1.8 bar (1.8/350). Changing
the driving pressure from 1.2 to 1.8 bar will
increase the airways pressure generated during
each percussion, where a decrease in frequency
will increase the volume of air delivered by the
machine during each pulsation. The patients were
instructed by the respiratory therapist to relax, but
not to try to keep the frequency of the ventilator.
Second trial
As shown in Fig. 1 middle part, 5 of 10 patients
underwent also an additional experimental proce-
dure at the end of the first trial. They were
randomly assigned to 2 sessions of IPV (1.2/250 and
1.8/250) and 1 of non-invasive PSV lasting 10min
each and separated by return to SB for 15min. Non-
invasive PSV was delivered using the same faceFigure 1 Protocol of the study. The COPD patients underwent
volunteers were studied during the third trial. SB ¼ sponta
250/min and driving pressure of 1.2 bar, 1.8/250 ¼ frequency
1.2/350 ¼ frequency of percussion of 350/min and driving p
350/min and driving pressure of 1.8 bar.mask, while the experimental apparatus (i.e.
location of the pneumotach and pressure transdu-
cers) was kept constant. The level of end-expira-
tory pressure was maintained constant at 3 cmH2O,
while the inspiratory pressure was set according to
the patient’s tolerance (14.272.1 cmH2O).
Oxygen was eventually supplied to those patients
with an SpO2o90%, directly into the mask to maintain
an oxygen saturation (SpO2)490% and was kept
constant throughout the experimental procedure.
Third trial
Five normal volunteers (2 females and 3 males,
mean age ¼ 38.874.1) were also studied, during 2
periods of apnea obtained with a breath-holding,
lasting at least 2min, separated by 15min of SB
(Fig. 1, lower part). The apnea trials were
performed during 2 sessions of IPV (1.2/250 and
1.8/250) delivered in random order. The trials were
performed without oxygen supply.
Measurements
The physiological variables were continuously dis-
played on a PC screen. SpO2 and heart rate were also
continuously monitored with a portable device.
Flow at the airway opening was measured with
a heated pneumotachograph (Hans-Rudolf 3700,
Kansas, USA) and a differential pressure transducer
(Honeywell7300 cmH2O; Freeport, IL, USA) placed2 different trials (first and second trial), while the normal
neous breathing, 1.2/250 ¼ frequency of percussion of
of percussion of 250/min and driving pressure of 1.8 bar,
ressure of 1.2 bar, 1.8/350 ¼ frequency of percussion of
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Physiological effects of percussive ventilation 1529between the mask and the ventilator tubings. VT
was obtained by digital integration of the flow using
the trapezoidal rule.8
Airway pressure (Honeywell7300 cmH2O; Free-
port, IL, USA) was measured from a side port
between the pneumotachograph and the face mask.
Esophageal and gastric pressures were measured
with a balloon–catheter system. To this aim, an
esophageal balloon positioned at the lower third of
the esophagus, filled with 0.5ml of air and a gastric
balloon filled with 1ml of air. The proper position of
the balloon was verified using the occlusion test.9
Transdiaphragmatic pressure (Pdi) was calculated
as the difference between gastric (Pga) and
esophageal (Pes) pressure.9
The pressure time integrals of the diaphragm was
calculated per breath (PTPdi/b) and per minute
(PTPdi/min).10
Respiratory mechanics were assessed using Mead
and Wittenberger’s technique.11 Inspiratory pul-
monary resistance (RL) and elastance (EL) were
calculated by fitting the equation of motion of
a single-compartment model using multilinear
regression.
Dynamic PEEPi (PEEPi,dyn) was measured accord-
ing to Appendini et al.12
Expiratory muscle recruitment during the differ-
ent trials was assessed by measuring the rise in Pga
during expiration from its end-inspiratory level to
the maximum at end-expiration.13,14
The patient’s tolerance to ventilation was eval-
uated on a visual analogue scale. This scale has
been used and validated in previous studies15,16 and
has 5 scores: 1, bad; 2, poor; 3, sufficient; 4, good;
5, very good. The patients were asked by the
respiratory therapist to answer the following
question: ‘‘How do you feel your breathing is at
this moment’’. For each condition tested, the
patient placed a finger on the number that best
represented the intensity of his or her dyspnoea.
The study was approved by the local Ethical
Committee and written informed consent was
obtained from the patients and normal subjects.
Statistics
Results are presented as mean7standard deviation
(SD) for continuous variables, as frequency or
percentage for the nominal variables and as median
(quartiles or range) for the ordinal variables.
Comparisons for each sequence and each contin-
uous variable were performed with one-way ANOVA
for repeated measures. Post hoc comparisons
between sequences were performed by using
Duncan’s test. Comparisons between the different
SB measurements were performed using the Krus-
kall–Wallis analysis of variance.To compare repeated measures for an ordinal
variable (patient tolerance) the Friedman test was
used, while internal comparisons were performed
using a non-parametrical test for multiple post hoc
comparisons.
All tests were two-sided. A P value o0.05 was
considered statistically significant.
Results
All the patients and normal subjects tolerated the
experimental procedure well, except for 2 patients
who could not stand the 1.2/350 trial and the
1.2/350 and 1.8/350. SpO2 was kept also constant
throughout the trials, without changing the FiO2 set
at SB. No statistical difference was observed in all
the physiological variables recorded between the
different periods of SB lasting 15min.
Ten minutes of IPV were able to induce a
homogeneous breathing pattern in our patients,
as already described in this population of stable
patients by another study using other types of
ventilatory support.17
First trial
Figure 2, upper part, is a recording from a
representative COPD patient.
Table 2 shows the main physiological changes
induced by IPV in the first experimental trial.
Minute ventilation was not statistically different
from SB during the IPV trials, since while VT was
significantly increased, respiratory rate decreased
even though not significantly. The PTPdi/min and
PTPdi/b, estimate of the diaphragm energy ex-
penditure was reduced, compared to SB, in all the
IPV trials, but significantly so only during those at
low frequency (1.2/250 and 1.8/250). Similar
changes were observed for the amount of
PEEPi,dyn.
Lung compliance and resistance did not signifi-
cantly change during the various ventilatory trials.
Tolerance to ventilation was not statistically
significant among the trails, but a larger propor-
tion of patients ranked the low-frequency trials
(1.2/250 and 1.8/250) as ‘‘good’’ or ‘‘very good’’.
The expiratory muscle recruitment was minimal
in most of the patients with actually only 2/10
subjects showed a rise in Pga during expiration
41 cmH2O at 1.8/350.
Second trial
Figure 3 shows the individual changes (different
symbols) in PTPdi/min at SB, 1.2/250,1.8/250 and
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Figure 2 Upper part ¼ traces of a representative COPD patient during the 4 runs and spontaneous breathing.
SB ¼ spontaneous breathing, 1.2/250 ¼ frequency of percussion of 250/min and driving pressure of 1.2 bar,
1.8/250 ¼ frequency of percussion of 250/min and driving pressure of 1.8 bar, 1.2/350 ¼ frequency of percussion of
350/min and driving pressure of 1.2 bar, 1.8/350 ¼ frequency of percussion of 350/min and driving pressure of 1.8 bar,
V ¼ airflow, Paw ¼ pressure at the airway, VT ¼ tidal volume, Pga ¼ gastric pressure, Pes ¼ esophageal pressure,
Pdi ¼ transdiaphragmatic pressure, lower part ¼ traces of a representative normal subject during the apnea breath-
holding trail, abbreviations are the same as for the upper part.
Table 2 Physiological changes induced by IPV (intrapulmonary percussive ventilation) during the first trial.
Variable SB 1.2/250 1.8/250 1.2/350 1.8/350
VE (l/m) 8.7372.5 9.7973.1 8.7172.9 9.1472.3 8.7773.7
VT (ml) 3557155 4457163
 4227175 4637123y 4427173
f (breath/min) 25.076.8 21.876.8 20.777.6 20.177.5 19.778.4
Ti (s) 1.1470.3 1.2370.4 1.2770.4 1.1670.3 1.2070.4
PTPdi/min (cmH2O s/min) 209.2777.9 143.1772.2 125.5760.4 141.17103.3 125.3783
PTPdi/b (cmH2O s) 8.574.2 6.873.6 6.172.6y 6.773.6 6.373.4
PEEPi,dyn (cmH2O) 2.470.9 1.171.0
y 1.370.6 1.570.9 1.971.1
RL (cmH2O/l s) 7.872.3 7.171.8 6.972.0 7.771.3 7.971.6
CL (cmH2O/l/s) 0.0770.01 0.0770.02 0.0870.02 0.0870.02 0.0770.03
SaO2 (%) 94.371.0 96.272.2 95.771.3 96.071.6 94.972.2
SB, spontaneous breathing.
1.2/250 ¼ frequency of percussion of 250/min and driving pressure of 1.2 bar.
1.8/250 ¼ frequency of percussion of 250/min and driving pressure of 1.8 bar.
1.2/350 ¼ frequency of percussion of 350/min and driving pressure of 1.2 bar.
1.8/350 ¼ frequency of percussion of 350/min and driving pressure of 1.8 bar.
VE, Minute ventilation; VT, tidal volume; f, respiratory frequency; Ti, inspiratory time; PTPdi/b, pressure time product of the
diaphragm per breath; PTPdi/min, pressure time product of the diaphragm/min; PEEPi,dyn, dynamic positive end-expiratory
pressure; RL, total resistance of the lungs; CL, lung compliance, SaO2, oxygen saturation.
Po0.05 from SB.
yPo0.01 from SB.
S. Nava et al.1530during non-invasive PSV in the 5 patients under-
going an additional trial with this latter mode of
ventilation. No significant differences were ob-
served between the IPV trials and PSV session, for
the PTPdi/b, and all the other physiological
recordings, as illustrated in Table 3.Third trial
The apnea trial was well tolerated by all
the normal subjects, and lasted on average
139718 s without any significant decrease in SaO2
under IPV.
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a typical normal subject. Complete absence of SB
can be depicted by the pressures traces.Discussion
IPV is one stand-alone technique of HFV, that was
initially employed for treating acute respiratory
failure due to different pathologies like burns18 and
smoke inhalation,19 closed head injury,20 hyaline
membrane disease and ARDS.21,22 More recently, it
has been also successfully and increasingly used in
those patients with cystic fibrosis,4 Duchenne
muscular dystrophy2 and other neuromuscular
diseases3 and exacerbated COPD,6 as a primary
treatment for mobilizing and clearing secretions.
Apart from an ‘‘in vitro’’ investigation8 that
assessed changes in flow, volume and pressure
waveforms after modification of resistance and
elastance, while maintaining the same ventilatory
settings, no study has systematically assessed theTable 3 Physiological changes induced by low freque
pressure support ventilation (PSV) in the second trial perf
Variable SB 1.2/250
VE (l/m) 7.58+3.1 8.81+4.4
PTPdi/b (cmH2O s) 7.7+4.8 5.8+3.9
PEEPi,dyn (cmH2O) 2.8+1.2 1.5+1.0
RL (cmH2O/l s) 8.3+3.3 8.4+2.9
CL (cmH2O/l/s) 0.08+0.02 0.07+0.0
SaO2 (%) 95.4+1.4 96.8+2.6
See Table 2 for abbreviations.
Po0.05 from SB.
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Figure 3 Individual changes in pressure time product of
the diaphragm per minute (PTPdi/min) in the second trial
performed in 5 patients. Each symbol is a different patient.
SB ¼ spontaneous breathing, 1.2/250 ¼ frequency of per-
cussion of 250/min and driving pressure of 1.2 bar,
1.8/250 ¼ frequency of percussion of 250/min and driving
pressure of 1.8bar, PSV ¼ non-invasive pressure support
ventilation.‘‘in vivo’’ physiological changes using the para-
meters commonly used during the non-invasive
treatment.
In order to avoid potential confounders, the
study was performed on stable patients with
minimal mucus production, since despite the
randomized nature of the trial, the mobilization
of massive secretion potentially induced by the
initial application of IPV, may have altered the
mechanical properties of the respiratory system,
influencing therefore the following runs with a
carry-over effect.
As a matter of fact both pulmonary compliance
and resistances were maintained constant during
the experimental procedures.
We have chosen to study COPD patients with
chronic respiratory failure since in this latter
population, it was recently demonstrated, during
an episode of exacerbation requiring ICU admis-
sion, that IPV may prevent further deterioration,
avoiding therefore the need for invasive mechan-
ical ventilation.6
In that study, several mechanisms of action for
IPV were postulated. Apart from the effect on
mucus clearance, it was suggested that an external
positive end-expiratory pressure (PEEPe) effect
and/or an HFV-like effect were possible.6
IPV maintains an intrapulmonary pressure to
stabilize the airway patency during the whole
respiratory cycle,1 so that this mechanism may
counterbalance the inspiratory load necessary start
inspiration when a positive end-expiratory pressure
is present in COPD patients.23 As a matter of fact
the amount of PEEPi,dyn was significantly reduced
during 1.2/250 and 1.8/250, suggesting a direct
effect of IPV. Indeed, no indirect signs of hyperin-
flation, such as a ‘‘notching’’ in the expiratory
phase of Pdi, were observed during the IPV trials.
Despite during an acute exacerbation of COPD,
the portion of energy expenditure of the diaphragm
(PTPdi), due to the presence of PEEPi,dyn is veryncy IPV (intrapulmonary percussive ventilation) and
ormed in 5 patients.
1.8/250 PSV
9.0+3.9 9.6+4.2
 5.5+4.0 4.9+3.6
 1.2+0.8 1.1+0.9
7.8+2.2 7.9+2.3
4 0.08+0.03 0.07+0.05
96.2+1.9 96.5+2.0
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S. Nava et al.1532consistent11 (40% of the total), in stable COPD,
like those included in the present study, it is
definitively less.23
Therefore the marked and statistically significant
decrease in PTPdi both per breath and per minute,
observed during IPV must be due also to a direct
‘‘ventilatory effect’’.
The PTPdi depends on the time of inspiration and
the tidal transdiaphragmatic pressure (Pdi) gener-
ated during each inspiration. Since IPV did not
significantly influence the respiratory timing, the
decrease in the metabolic consumption was pre-
sumably due to the use of a lower portion of Pdi, as
repeatedly demonstrated during any form of
invasive or non-invasive mechanical support of
ventilation.23,24
Indeed the physiological changes induced by IPV
were very similar to those obtained in 5 patients
during the most commonly used mode of non-
invasive ventilation (i.e. PSV).23,24 The comparison
of different modes of ventilation must be anyhow
taken with caution, since the matching of the
physiological variables (i.e. VT, mean airways
pressure or minute ventilation) is very difficult o
achieve.
Having said that, IPV could be considered a form
of full ventilatory support. To confirm this all the 5
normal subjects enrolled for the prolonged apnea
trial without oxygen supply, could successfully
sustain the breath holding for more than 2min
without any drop in SaO2. It may be therefore
suggested that IPV may be safely used also in those
tracheotomized patients with absent or minimal
ventilator autonomy (i.e. spinal cord injury or
amyotrophic lateral sclerosis), when they need to
be disconnected from their usual ventilator in order
to mobilize their secretions.
Last, IPV was well tolerated, but overall the low-
frequency trials were better accepted. Indeed, it
has also been suggested that the application of a
continuous positive intrapulmonary pressure, may
increase the activation of the expiratory muscles.25
This was not the case in the large majority of our
patients (8/10), that did not show a significant Pga
rise during expiration.13,14
The assessment of the clinical usefulness of IPV in
stable COPD and its potential fields of application
were beyond the aim of this physiological study, so
that further studies are clearly needed to confirm
the potential role of IPV to manage patients
undergoing an acute exacerbation of their chronic
obstructive disease.
In this first physiological study performed in
stable COPD patients with chronic respiratory
failure, we have demonstrated that the application
of IPV is associated with a significant reduction ofthe diaphragm energy expenditure, probably
mediated by a ‘‘true ventilatory’’ effect. Indeed,
it is safe, and overall well tolerated, especially
with the lower frequencies. Further studies may be
needed to extrapolate these results to more acute
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